Pear Therapeutics Stock

peartherapeutics.comHealthcare / Digital HealthFounded: 2013Funding to Date: $139MM

Pear discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers.

Register To Buy and Sell Shares

For more details on financing and valuation for Pear Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Pear Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Pear Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Alex Waldron
Chief Commercial Officer
Stephen Smith JD
Co-Founder & Executive Vice President of Corporate Development
Walter Greenleaf Ph.D
Chief Science Advisor
Christopher Guiffre JD
Chief Operating Officer & Chief Financial Officer
Yuri Maricich MD
Chief Medical Officer & Head of Clinical Development
Jeffrey Lieberman
Advisor
Corey McCann Ph.D
Co-Founder, President, Chief Executive Officer & Board Member
Jeremy Gilbert
Chief Product Officer
Beth Rogozinski
Chief Content Advisor

Board Members

Andrew Schwab
5AM Ventures
John Harris
JAZZ Venture Partners
Zack Lynch
JAZZ Venture Partners
Corey McCann Ph.D
Jeremy Sohn
Timothy Petersen
Arboretum Ventures
Delaine Cheong
Temasek Holdings
Jamil Beg
5AM Ventures
Thomas Shehab MD
Arboretum Ventures
Hu Hongjie
Temasek Holdings

News Highlights

Pear Therapeutics rakes in $64M for reSET commercialization, product development
The latest funding was led by Temasek, with participation from Novartis, 5AM Ventures, Arboretum Ventures, Jazz Partners, The Bridge Builders Collaborative and EDBI.
Updated on: May 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.